194 related articles for article (PubMed ID: 29372560)
1. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y
Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560
[TBL] [Abstract][Full Text] [Related]
2. Short divalent ethacrynic amides as pro-inhibitors of glutathione
Xu B; Tong T; Wang X; Liu F; Zhang X; Hu X; Li X; Yang X; Liao F
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):728-742. PubMed ID: 35176963
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
[TBL] [Abstract][Full Text] [Related]
4. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells].
Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY
Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028
[TBL] [Abstract][Full Text] [Related]
5. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
Park J; Park SY; Kim JH
Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression.
Endo H; Hama N; Baghdadi M; Ishikawa K; Otsuka R; Wada H; Asano H; Endo D; Konno Y; Kato T; Watari H; Tozawa A; Suzuki N; Yokose T; Takano A; Kato H; Miyagi Y; Daigo Y; Seino KI
Int Immunol; 2020 Mar; 32(3):175-186. PubMed ID: 31868884
[TBL] [Abstract][Full Text] [Related]
8. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
9. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
Li E; Hu Z; Sun Y; Zhou Q; Yang B; Zhang Z; Cao W
Tumour Biol; 2016 Jun; 37(6):7843-52. PubMed ID: 26695152
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
12. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Masanek U; Stammler G; Volm M
Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
[TBL] [Abstract][Full Text] [Related]
13. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
Wang H; Luo Y; Qiao T; Wu Z; Huang Z
J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
[TBL] [Abstract][Full Text] [Related]
14. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.
Pass HI; Lavilla C; Canino C; Goparaju C; Preiss J; Noreen S; Blandino G; Cioce M
Oncotarget; 2016 Aug; 7(35):56408-56421. PubMed ID: 27486763
[TBL] [Abstract][Full Text] [Related]
17. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
18. IGF-1R anti-idiotypic antibody antagonist exhibited anti-ovarian cancer bioactivity and reduced cisplatin resistance.
Weiwei Z; Ya X; Wenwen W; Jia J; Jing B; Ruitao Z; Chunfang W; Ruixia G
Hum Cell; 2021 Jul; 34(4):1197-1214. PubMed ID: 33905103
[TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency.
Li N; Chu Y; Yao L; Ying X; Jiang H; Zhou M; Xu C
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1455-61. PubMed ID: 21809030
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
